Clinical Studies of Recombinant Human C1 Inhibitor (rhC1INH) in Patients with Acute Attacks of Hereditary Angioedema

Clinical Studies of Recombinant Human C1 Inhibitor (rhC1INH) in Patients with Acute Attacks of Hereditary Angioedema

Methods The safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of intravenously administered rhC1INH were evaluated in open-label dose-escalation studies in asymptomatic HAE patients, in open-label Phase II studies treating severe acute HAE attacks as well as in randomiz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2008-03, Vol.121 (3), p.797-797
Hauptverfasser: Nuijens, J, Verdonk, R, Giannetti, B, Visscher, S, van Doorn, M, Resink, T, Levi, M, Hack, C, Farkas, H, Obtulowicz, K, Caballero, T, Cicardi, M
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Drug therapy
Studies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Methods The safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of intravenously administered rhC1INH were evaluated in open-label dose-escalation studies in asymptomatic HAE patients, in open-label Phase II studies treating severe acute HAE attacks as well as in randomized, placebo-controlled, double-blind Phase III studies.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2008.01.061